OGN — Organon & Co.

—
NYSE · Health Care · Pharmaceuticals · CIK 1821825 ·
Last close
$13.90
Market Cap
$3.65B
52W High
$13.91
52W Low
$5.67
ADV30
2,622,918
Next earnings
2026-10-30

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,574,000,000 869,000,000 365,000,000 164,000,000 13,401,000,000 1,455,000,000 12,208,000,000
Jun 2026 1,558,000,000 847,000,000 323,000,000 108,000,000 13,178,000,000 1,132,000,000 12,172,000,000
Mar 2026 1,460,000,000 783,000,000 266,000,000 146,000,000 12,996,000,000 1,116,000,000 12,093,000,000
Dec 2025 1,507,000,000 741,000,000 217,000,000 -205,000,000 12,867,000,000 574,000,000 12,115,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$737,000,000
Investing CF
$130,000,000
Financing CF
$-313,000,000
CapEx
$-303,000,000
Dividends Paid
$-18,000,000
Buybacks
—
EPS Diluted TTM
$0.77
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$1,352,000,000
Inventory
$1,351,000,000
Receivables
$1,492,000,000
ST Investments
—
EBIT TTM
$959,000,000
Pretax Income TTM
$491,000,000
Interest Exp TTM
$468,000,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,098,999,808
EBITDA
$1,582,000,000
Free Cash Flow
$747,000,000
Enterprise Value
$10,733,682,688
Total Cash
$1,455,000,064
Total Debt
$8,553,999,872
Shares Out
262,621,584
Trailing EPS
$0.78
Book Value
$4.54
ROE
20.3%
ROA
5.7%
Div Yield
0.58%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,216,000,000 1,226,000,000 187,000,000 12,867,000,000 12,115,000,000 752,000,000 700,000,000
Dec 2024 6,403,000,000 1,486,000,000 864,000,000 13,101,000,000 12,629,000,000 472,000,000 939,000,000
Dec 2023 6,263,000,000 1,327,000,000 1,023,000,000 12,058,000,000 12,128,000,000 -70,000,000 799,000,000
Dec 2022 6,174,000,000 1,705,000,000 917,000,000 10,955,000,000 11,847,000,000 -892,000,000 858,000,000

TTM Snapshot

Revenues TTM
$6,127,000,000
NetIncome TTM
$209,000,000
OpCashFlow TTM
—
Assets (Latest)
$13,178,000,000
Forward EPS
$3.65

Max Pain — expiry 2027-01-15

max pain strike: $10.00 · spot: $13.92 · call oi: 1,495 · put oi: 8,184

Peers — same industry

TickerNameMarket CapLastDaily %
ABCL AbCellera Biologics Inc. $3.60B $11.03 —
TNGX Tango Therapeutics, Inc. $3.75B $22.11 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —
XENE Xenon Pharmaceuticals Inc. $3.81B $38.78 —
PBLS Parabilis Medicines, Inc. $3.49B $28.25 —

News headlines (Yahoo Finance, 1h cache)

Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
2026-11-12 15:00 · Yahoo
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
2026-11-10 13:00 · Yahoo
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Aff
2026-11-07 15:00 · Yahoo
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
2026-11-05 13:00 · Yahoo
Organon (OGN) Q3 Results Highlight A Thin Margin Cushion
2026-11-01 05:10 · Yahoo
Organon (OGN) Q3 Earnings and Revenues Top Estimates
2026-10-30 12:30 · Yahoo
Organon: Q3 Earnings Snapshot
2026-10-30 12:26 · Yahoo
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
2026-10-27 12:00 · Yahoo
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
2026-10-26 12:00 · Yahoo
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
2026-10-19 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.